290 related articles for article (PubMed ID: 24749785)
41. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice.
Garcia TC; Fonseca CT; Pacifico LG; Durães Fdo V; Marinho FA; Penido ML; Caliari MV; de Melo AL; Pinto HA; Barsante MM; Cunha-Neto E; Oliveira SC
Acta Trop; 2008 Jun; 106(3):162-7. PubMed ID: 18423420
[TBL] [Abstract][Full Text] [Related]
42. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis.
Tran MH; Pearson MS; Bethony JM; Smyth DJ; Jones MK; Duke M; Don TA; McManus DP; Correa-Oliveira R; Loukas A
Nat Med; 2006 Jul; 12(7):835-40. PubMed ID: 16783371
[TBL] [Abstract][Full Text] [Related]
43. Sm-p80-based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse.
Zhang W; Ahmad G; Torben W; Siddiqui AA
Parasite Immunol; 2010 Apr; 32(4):252-8. PubMed ID: 20398225
[TBL] [Abstract][Full Text] [Related]
44. Sm16, A
Bernardes WPOS; de Araújo JM; Carvalho GB; Alves CC; de Moura Coelho AT; Dutra ITS; Teixeira SSF; de Azambuja Ribeiro RIM; de Moraes Mourão M; da Silva-Pereira RA; Fonseca CT
J Immunol Res; 2019; 2019():6793596. PubMed ID: 31886307
[TBL] [Abstract][Full Text] [Related]
45. Vaccination against Schistosoma mansoni infection using 74 kDa Schistosoma protein antigen.
Attallah AM; Attia H; Ismail H; Yones E; El-Nashar EM; Abd El-Kader K; Tabll A; Saad A; Sultan A
Vaccine; 1999 Jul; 17(22):2786-91. PubMed ID: 10438048
[TBL] [Abstract][Full Text] [Related]
46. The use of gold nanorods as a new vaccine platform against schistosomiasis.
Assis NRG; Caires AJ; Figueiredo BC; Morais SB; Mambelli FS; Marinho FV; Ladeira LO; Oliveira SC
J Control Release; 2018 Apr; 275():40-52. PubMed ID: 29428201
[TBL] [Abstract][Full Text] [Related]
47. A vaccine consisting of Schistosoma mansoni cathepsin B formulated in Montanide ISA 720 VG induces high level protection against murine schistosomiasis.
Ricciardi A; Visitsunthorn K; Dalton JP; Ndao M
BMC Infect Dis; 2016 Mar; 16():112. PubMed ID: 26945988
[TBL] [Abstract][Full Text] [Related]
48. Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells.
Fonseca CT; Cunha-Neto E; Kalil J; Jesus AR; Correa-Oliveira R; Carvalho EM; Oliveira SC
Mem Inst Oswaldo Cruz; 2004; 99(5 Suppl 1):63-6. PubMed ID: 15486637
[TBL] [Abstract][Full Text] [Related]
49. Immunization against Egyptian Schistosoma mansoni infection by multivalent DNA vaccine.
Romeih MH; Hassan HM; Shousha TS; Saber MA
Acta Biochim Biophys Sin (Shanghai); 2008 Apr; 40(4):327-38. PubMed ID: 18401531
[TBL] [Abstract][Full Text] [Related]
50. Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis.
Chura-Chambi RM; Nakajima E; de Carvalho RR; Miyasato PA; Oliveira SC; Morganti L; Martins EA
J Biotechnol; 2013 Dec; 168(4):511-9. PubMed ID: 24084635
[TBL] [Abstract][Full Text] [Related]
51. Simultaneous priming with DNA encoding Sm-p80 and boosting with Sm-p80 protein confers protection against challenge infection with Schistosoma mansoni in mice.
Le L; Zhang W; Karmakar S; Ahmad G; Torben W; Siddiqui AA
Parasitol Res; 2014 Mar; 113(3):1195-200. PubMed ID: 24452916
[TBL] [Abstract][Full Text] [Related]
52. Rational selection of immunodominant and preserved epitope Sm043300e from Schistosoma mansoni and design of a chimeric molecule for biotechnological purposes.
de Souza C; Lopes MD; De Oliveira FM; Passos MJF; Ferreira LCG; Faria BF; Villar JAFP; Junior MC; Taranto AG; Dos Santos LL; Fonseca CT; de Oliveira Lopes D
Mol Immunol; 2018 Jan; 93():133-143. PubMed ID: 29175593
[TBL] [Abstract][Full Text] [Related]
53. Human IgG1 Responses to Surface Localised Schistosoma mansoni Ly6 Family Members Drop following Praziquantel Treatment.
Chalmers IW; Fitzsimmons CM; Brown M; Pierrot C; Jones FM; Wawrzyniak JM; Fernandez-Fuentes N; Tukahebwa EM; Dunne DW; Khalife J; Hoffmann KF
PLoS Negl Trop Dis; 2015; 9(7):e0003920. PubMed ID: 26147973
[TBL] [Abstract][Full Text] [Related]
54. Immunoprotection of mice against Schistosomiasis mansoni using solubilized membrane antigens.
Sulbarán G; Noya O; Brito B; Ballén DE; Cesari IM
PLoS Negl Trop Dis; 2013; 7(6):e2254. PubMed ID: 23818994
[TBL] [Abstract][Full Text] [Related]
55. Protective capacity of cercarial transformation fluid alone or in combination with crude cercarial antigen against challenge infections of Schistosoma mansoni in mice.
El Azzouni MZ; Mady RF; Gaafar MR; Arafa FM; Elhadidi A
J Helminthol; 2017 Jan; 91(1):35-42. PubMed ID: 26817577
[TBL] [Abstract][Full Text] [Related]
56. Co-administration of plasmid expressing IL-12 with 14-kDa Schistosoma mansoni fatty acid-binding protein cDNA alters immune response profiles and fails to enhance protection induced by Sm14 DNA vaccine alone.
Fonseca CT; Pacífico LG; Barsante MM; Rassi T; Cassali GD; Oliveira SC
Microbes Infect; 2006 Aug; 8(9-10):2509-16. PubMed ID: 16914349
[TBL] [Abstract][Full Text] [Related]
57. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area.
Keitel WA; Potter GE; Diemert D; Bethony J; El Sahly HM; Kennedy JK; Patel SM; Plieskatt JL; Jones W; Deye G; Bottazzi ME; Hotez PJ; Atmar RL
Vaccine; 2019 Oct; 37(43):6500-6509. PubMed ID: 31515141
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of recombinant protein r140, a polypeptide segment of tegumental glycoprotein Sm25, as a defined antigen vaccine against Schistosoma mansoni.
Suri PK; Goldberg M; Madikizela M; Petzke MM; Bungiro RD; Davies SJ; Chakraborty B; Nguyen KB; McCray JW; Knopf PM
Parasite Immunol; 1997 Nov; 19(11):515-29. PubMed ID: 9427998
[TBL] [Abstract][Full Text] [Related]
59. Schistosoma mansoni gene GP22 encodes the tegumental antigen sm25: (1) antibodies to a predicted B-cell epitope of Sm25 cross-react with other candidate vaccine worm antigens; (2) characterization of a recombinant product containing tandem-repeats of this peptide as a vaccine.
Petzke MM; Suri PK; Bungiro R; Goldberg M; Taylor SF; Ranji S; Taylor H; McCray JW; Knopf PM
Parasite Immunol; 2000 Aug; 22(8):381-95. PubMed ID: 10972845
[TBL] [Abstract][Full Text] [Related]
60. Protection and immunological study on two tetraspanin-derived vaccine candidates against schistosomiasis japonicum.
Chen L; Chen Y; Zhang D; Hou M; Yang B; Zhang F; Zhang W; Luo X; Ji M; Wu G
Parasite Immunol; 2016 Oct; 38(10):589-98. PubMed ID: 27189226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
